An inhibitory effect of 3'-azido-3'-deoxythymidine triphosphate on hepatitis B virus DNA polymerase was found. No effect was seen by its threo analog. The effect was detected at and above a concentration of 0.05 microM. The inhibition of DNA polymerase activity was the same in ten different strains
Inhibition of hepatitis B virus DNA polymerase by 3′-fluorothymidine triphosphate and other modified nucleoside triphosphate analogs
✍ Scribed by H. Meisel; K. Reimer; M. V. Janta-Lipinski; D. Bärwolff; E. Matthes
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 422 KB
- Volume
- 30
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The 3′‐fluoromodified nucleotide analogs 3′‐fluorothymidine triphosphate (FdTTP), 2′,3′‐dideoxy‐3′‐fluoro‐5‐chlorouridine triphosphate (F‐5CldUTP), 2′,3′‐dideoxy‐3′‐fluoro‐5‐ethyluridine triphosphate (F‐5EtdUTP), 2′,3′‐dideoxy‐3′‐fluorouridine triphosphate (FdUTP), and 2′,3′‐dideoxy‐3′‐fluoro‐5‐fluorouridine triphosphate (F‐5FdUTP) as well as 2′,3′‐dideoxythymidine triphosphate (ddTTP), 2′,3′‐didehydro‐2′,3′‐dideoxythymidine triphosphate (ddeTTP), 3′‐chlorothymidine triphosphate (CldTTP), and 3′‐rhodanothymidine triphosphate (SCNdTTP) were tested for their ability to inhibit hepatitis B virus (HBV)‐associated DNA polymerase activity in vitro. The ID~50~ values of the most potent inhibitors were 0.15 μM for FdTTP, 0.2 μM for ddeTTP, 0.45 μM for ddTTP, and 0.8 μM for F‐5CldUTP. SCNdTTP, CldTTP, and F‐5EtdUTP were less efficient (ID~50~ = 3–5 μM), and FdUTP and F‐5FdUTP were the least efficient inhibitors (ID~50~ = 25 μM) of the enzyme activity. Kinetic analysis revealed a competitive type of inhibition for FdTTP and ddeTTP. The K~i~ values were estimated to be 0.04 μM and 0.08 μM, respectively, compared with a K~m~ value for dTTP of about 0.18 μM.
📜 SIMILAR VOLUMES
The deoxyguanosine analog penciclovir (PCV; 9-[4-hydroxy-3-hydroxymethyl-but-1-yl]guanine), has shown potent antiviral activity against herpes viruses and hepadnaviruses. Efficacy against chronic hepatitis B virus (HBV) infection has been demonstrated in an animal model and in recent clinical trials
Hepatitis B virus (HBV) replication is mediated by the effective vaccines against hepatitis B virus (HBV) usviral polymerase that possesses three functional doing surface antigens have been developed, there are mains: primer, DNA polymerase/reverse transcriptase, still approximately 300 million carr